Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome-wide gene expression analysis of the cancer cell lines after treatiment with telomerase inhibitor Imetelstat (GRN163L)

ABSTRACT: GRN163L is a potent and specific telomerase inhibitor and in clinical trials for cancer treatment. To identify the biomarker that might predict response to telomease based therapy, gene expression analysis of the cancer cell lines after treatiment with telomerase inhibitor Imetelstat (GRN163L) was performed.

ORGANISM(S): Homo sapiens

PROVIDER: GSE106539 | GEO | 2018/07/19

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Telomerase inhibitor TMPyP4 induced gene expression

Project description:The effect of TMPyP4, the well established anticancer telomerase inhibitor on genome wide expression of genes was investigated Keywords: Time course

2007-06-20 | GSE5226 | GEO

Telomerase inhibitor TMPyP4 induced widespread gene expression

2008-08-25 | GSE9710 | GEO

Telomerase inhibitor TMPyP4 induced gene expression

Project description:The effect of TMPyP4, the well established anticancer telomerase inhibitor on genome wide expression of genes was investigated Keywords: Time course Cells were treated with TMPyP4 for either 24 or 48 hours before RNA isolation.Untreated cells were taken as controls and the TMPyP4 treated cells as treatments. Experiments at each time point were replicated four times.

2010-06-10 | E-GEOD-5226 | biostudies-arrayexpress

Telomerase inhibitor TMPyP4 induced widespread gene expression

Project description:The effect of TMPyP4, the well established anticancer telomerase inhibitor on genome wide expression of genes, analyzed across different cell-lines, was investigated Keywords: Comparative gene-expression profiling Cells were treated with TMPyP4 for 48 hours before RNA isolation. Untreated cells were taken as controls and the TMPyP4 treated cells as treatments. Experiments in each cell-line (A549 and HeLa S3) were replicated four times.

2010-06-20 | E-GEOD-9710 | biostudies-arrayexpress

MST-312: a telomerase inhibitor effectively blocking MYC oncogenic functions [array]

Project description:Reactivation of the telomerase reverse transcriptase subunit, TERT, is linked to tumourigenesis due to well-documented telomere-dependent and independent functions. The aim of this study was to investigate the effect of the telomerase inhibitor, MST-312, on TERT functions, focusing in particular, on its effects on MYC stabilty and MYC-regulated pathways, in order to assess its potential as a therapeutic agent. We demonstrate that MST-312 reduces MYC levels in cancer cells, leading to reduced MYC levels on chromatin, and subsequently affecting the MYC-regulated transcriptional program. As a result, MST-312 treatment increases the survival of lymphoma-bearing mice. Mechanistically, MST-312 affects the conformation of TERT, leading to TERT/Terc dissociation, and the subsequent loss of both its telomere-dependent and independent functions. Based on the presented data, we conclude that MST-312 treatment is a promising therapeutic strategy, in particular, in MYC-driven tumorus.

2020-01-01 | GSE77014 | GEO

MST-312: a telomerase inhibitor effectively blocking MYC oncogenic functions [ChIP-Seq]

2020-01-01 | GSE77061 | GEO

MST-312: a telomerase inhibitor effectively blocking MYC oncogenic functions

Project description:MST-312: a telomerase inhibitor effectively blocking MYC oncogenic functions

| PRJNA309377 | ENA

Transcriptome-wide gene expression analysis of the cancer cell lines after treatiment with telomerase inhibitor Imetelstat (GRN163L)

Project description:Transcriptome-wide gene expression analysis of the cancer cell lines after treatiment with telomerase inhibitor Imetelstat (GRN163L)

| PRJNA417570 | ENA

Genome-wide transcriptional profiling of primary human AML samples with distinct susceptibilities to telomerase inhibition

Project description:Analysis of gene expression profiles of human AML patient samples. The hypothesis tested was that AML patient samples showing a higher sensitivity to subsequent telomerase inhibition would already harbour a telomerase deficiency gene expression signature before treatment that may be useful to predict therapeutic efficacy. The results provide a clear separation of AML patient samples based on a telomerase deficiency gene signature that is correlated with subsequent sensitivity to pharmacologic telomerase inhibition assessed in a xenograft transplantation system in vivo.

2014-11-11 | GSE63146 | GEO

MAT2A inhibitor in cancer cell lines

Project description:MAT2A inhibitor in cancer cell lines

| PRJNA679231 | ENA